Formed in 2010, Syapse’s services enable healthcare providers to implement precision medicine through its software platform, data sharing network, and industry partnerships. Medidata, which provides cloud-based technology and data analytics for clinical research, has partnered with the San Francisco, CA-based company to “transform oncology clinical trials for the age of precision medicin​e.” Glen de Vries, Medidata president and co-founder, told us the “ultimate objective is to allow trial sponsors to accelerate the process of clinical research in oncology​.” Medidata's solutions are used by 18 of the top 25 pharmaceutical companies, while Syapse’s solutions power precision medicine for nearly 300 hospitals across the US. Through the partnership, the companies aim to scale a new product offering to pharmaceutical companies and health systems. “We will build a suite of solutions that will focus on optimizing trial eligibility criteria based on true patient availability, expanding access to innovative trials by bringing them to community sites, and making it easier for oncologists and their care teams identify and enroll patients​,” said de Vries. “While precision medicine is a promising area of research, there are challenges associated with focusing on even smaller segments of patients,” ​he added. “Our partnership with Syapse will help address these challenges​.”
Medidata and US are partnering up to help trial sponsors accelerate clinical research into precision medicine for use in oncology. US software powers precision medicine for nearly 300 Syapse hospitals, while Medidata's cloud-based technology and data analytics systems are used by 18 of the top 25 pharmaceutical firms. The pair hope to build a range of solutions that optimise trial eligibility criteria and make it easier for specialists to identify and enrol patients, said Glen de Vries, president of Medidata.